SEERMEDIUM SIGNALFINANCIAL10-K

SEER shows improving operational efficiency with reduced operating losses and growing revenue, but concerning equity dilution and asset decline suggest ongoing cash burn challenges.

The company is demonstrating operational progress with 17% revenue growth and 22% improvement in operating losses while cutting SG&A expenses by 25%, indicating better cost discipline. However, the 21% decline in stockholders' equity combined with asset reduction signals continued cash consumption that may pressure future financing needs.

Comparing 2026-03-02 vs 2025-03-03View on EDGAR →
FINANCIAL ANALYSIS

SEER's financial picture shows mixed signals with positive operational trends but concerning balance sheet deterioration. Revenue grew 17% to $16.6M with improved gross profit and significantly reduced operating losses (-$78M vs -$100M), while SG&A costs fell 25%, demonstrating better operational efficiency. However, stockholders' equity declined 21% to $259M and total assets fell 19%, indicating substantial cash burn that outweighed the operational improvements, though the company maintains adequate liquidity with $47M in cash.

FINANCIAL STATEMENT CHANGES
Accounts Receivable
Balance Sheet
+72.9%
$2.5M$4.3M

Receivables surged 72.9% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Capital Expenditure
Cash Flow
-49.9%
$3.6M$1.8M

Capex reduced 49.9% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

SG&A Expense
P&L
-24.7%
$56.6M$42.6M

SG&A reduced 24.7% — improved cost efficiency or headcount reduction improving operating margins.

Operating Income
P&L
+22.1%
-$100.1M-$78.0M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Stockholders Equity
Balance Sheet
-20.8%
$327.6M$259.3M

Equity decreased 20.8% — buybacks or losses reducing book value, monitor solvency ratios.

Current Assets
Balance Sheet
-20.4%
$253.3M$201.5M

Current assets declined 20.4% — monitor working capital adequacy and short-term liquidity.

Gross Profit
P&L
+20%
$7.1M$8.5M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Total Assets
Balance Sheet
-19.2%
$366.6M$296.1M

Total assets contracted 19.2% — asset sales, write-downs, or balance sheet optimization underway.

Revenue
P&L
+17%
$14.2M$16.6M

Revenue growing 17% — solid top-line momentum, watch margins for quality of growth.

Cash & Equivalents
Balance Sheet
+16%
$40.8M$47.3M

Cash grew 16% — improving liquidity position supports investment and shareholder returns.

LANGUAGE CHANGES
NEW — 2026-03-02
PRIOR — 2025-03-03
ADDED
As of February 23, 2026, the registrant had 56,420,772 shares of Class A common stock, $0.00001 par value per share, outstanding.
Through our product, the Proteograph Product Suite (Proteograph), we provide researchers with unbiased, deep, rapid and large-scale access to the proteome, enabling biological discovery that has historically been impractical.
With our pioneering proprietary engineered nanoparticle (NP) technology and the Proteograph Product Suite, we provide the most complete, precise, and scalable platform for deep, unbiased proteomics to power population-scale studies and data-driven biology.
Proteins are the functional drivers of biology and the primary targets of most approved drugs.
Unlike DNA, which is largely static over an individual s lifetime, the proteome is dynamic, reflecting real-time biological processes, disease states, and responses to therapeutic intervention.
+7 more — sign up free →
REMOVED
As of February 26, 2025, the registrant had 55,737,066 shares of Class A common stock, $0.00001 par value per share, and 4,044,969 of Class B common stock, $0.00001 par value per share, outstanding.
Through our product, the Proteograph TM Product Suite (Proteograph), we provide researchers with unbiased, deep, rapid and large-scale access to the proteome.
With our pioneering development of the Proteograph, its unique capabilities and growing body of scientific evidence, we believe researchers view us as their trusted partner in unlocking novel biological insights that were previously beyond reach.
Since our commercial launch in 2021, we have served more than 135 customers in over 20 countries to enable them to drive scientific discoveries and innovation.
The Proteograph is a comprehensive solution that includes consumables, an automation instrument and data analysis software.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →